RxDoctor Payments Data

Jeffrey Gelblum, MD

Neurology · Aventura, FLNPI 1124057898

Payments from drug & device makers

$324,384in general payments, 2019–2025

Across 979 payments — averaging $331.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$107K
  • Corium, LLC$42K
  • Lilly USA, LLC$36K
  • Alnylam Pharmaceuticals Inc.$30K
  • AstraZeneca$22K
  • Otsuka America Pharmaceutical, Inc.$21K
  • plus $67K from 54 others

What the payments were for

  • Consulting fees$55,88917%
  • Speaking & faculty fees$208,82165%
  • Travel & lodging$36,43711%
  • Food & beverage$22,4567%
  • Education$510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.156$107,018
Corium, LLC66$42,304
Lilly USA, LLC84$35,776
Alnylam Pharmaceuticals Inc.45$29,535
AstraZeneca(2 entities)73$21,685
Otsuka America Pharmaceutical, Inc.30$20,882
Biogen29$19,761
Akcea Therapeutics, Inc.16$13,866
C2n Diagnostics, LLC25$13,682
Life Molecular Imaging Ltd10$7,838
AbbVie(2 entities)117$2,326
Eli Lilly2$848
Dr.reddy's Laboratories,inc.1$799
UCB, Inc.29$766
Pfizer32$708
Neurocrine Biosciences, Inc.32$619
Argenx US, Inc.21$616
Abbott16$596
Teva Pharmaceuticals USA, Inc.21$498
Lundbeck LLC17$437
Amgen19$377
ANI Pharmaceuticals, Inc.14$374
Merz Pharmaceuticals, LLC16$353
Novartis13$314
Amneal Pharmaceuticals LLC13$290
Takeda Pharmaceuticals U.S.A., Inc.10$235
Greenwich Biosciences, Inc.5$233
Revance Therapeutics, Inc.5$125
Jazz Pharmaceuticals Inc.4$122
Johnson & Johnson3$105
MDD US Operations, LLC4$97
EMD Serono, Inc.4$91
Acadia Pharmaceuticals Inc3$81
Tanabe Pharma America, Inc.3$77
Mallinckrodt Hospital Products Inc.3$71
Vanda Pharmaceuticals Inc.3$67
Averitas Pharma Inc.2$60
Kyowa Kirin, Inc.3$56
Octapharma USA, Inc.2$56
SK Life Science, Inc.2$45
Biohaven Pharmaceuticals, Inc.2$43
CSL Behring2$40
Livanova USA, Inc.2$39
Avion Pharmaceuticals2$36
TG Therapeutics, Inc.1$32
Boston Scientific1$31
Axsome Therapeutics, Inc.1$31
Sumitomo Pharma America, Inc.1$29
Globus Medical1$29
Bristol Myers Squibb2$28
Brainsway USA Inc1$28
Genentech USA, Inc.1$27
GRT US Holding, Inc.1$26
Biohaven Pharmaceutical Holding Company Ltd.1$26
Hyperfine Operations, Inc.1$25
Aucta Pharmaceuticals, Inc.1$25
Bausch Health US, LLC1$24
Acorda Therapeutics, Inc1$21
Alfasigma USA, Inc.1$19
Insightec,inc1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$324,384 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$2,011,936
Medicare patients
756
Services billed
88,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$327,115
GammakedImmune Globul G/Gly/Iga Avg 4620$315,747
Gamunex-CImmune Globul G/Gly/Iga Avg 4611$124,532
RexultiBrexpiprazole20$28,896
Aimovig AutoinjectorErenumab-Aooe18$17,805
RytaryCarbidopa/Levodopa13$16,882
Rasagiline Mesylate20$4,075
Pregabalin43$1,781
Donepezil Hcl166$1,740
Gabapentin97$1,581
Quetiapine Fumarate18$1,495
Memantine Hcl63$1,393
Oxcarbazepine37$1,157
Primidone40$1,094
Duloxetine Hcl34$902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$235$327,11512 claims
Otsuka America Pharmaceutical, Inc.Rexulti$20,882$28,89620 claims
Amneal Pharmaceuticals LLCRytary$290$16,88213 claims
Dr.reddy's Laboratories,inc.Pregabalin, Levetiracetam$799$2,14558 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →